Tafero

Tafero 25 mg

Tafero 25 mg (Tenofovir Alafenamide) belongs to the class of anti-viral medications employed for managing human immunodeficiency virus (HIV) type 1 and Chronic Hepatitis B Viral (HBV) infections. Tafero 25 mg (Tenofovir Alafenamide) has many benefits, including,

• •  Prevention or slowing down of the duplication process of the viruses

• •  Decreasing the proliferation of new viral cells in the system

• •  Clears the viral load from the system

• •  Increases the immunity power by enabling the growth of white blood cells (CD4), which protects against infection

• •  High efficiency with ten times lower dose than Tenofovir Disoproxil Fumarate

Administration of Tafero 25 mg (Tenofovir Alafenamide):

Disease type

Underlying condition

Dosage regimen

Mode of administration

HBV

Compensated (with a functional system) liver disease

1 tablet of 25 mg

Orally with food once daily

HIV-1

Treatment-naïve

1 tablet of 25 mg plus anti-retroviral drugs

Tafero 25 mg (Tenofovir Alafenamide) dosage in different populations:

Mild, moderate, or severe kidney impairments: 1 tablet of 25 mg once daily

End-stage kidney disease: Not recommended

Mild liver impairments:  1 tablet of 25 mg once daily

Decompensated (without a functional system) liver disease: Not recommended

Side-effects of Tafero 25 mg (Tenofovir Alafenamide):

Common side-effects:

• •  Headache

• •  Tiredness (Fatigue)

• •  Nausea

• •  Pain in the stomach region and back

• •  Cough

Severe side-effects:

Lactic acidosis (High lactic acid in the blood)

Liver complications

Unusual tiredness

Jaundice

Shortness of breath (Dyspnea)

Abdominal pain

Fast breathing

Urine in blackish-brown colour

Dizziness and Vomiting

Stools in a light colour

Cold or blue hands and feet

Nausea

Abnormal heartbeats

Loss of urge to eat

Note: Please discuss with your doctor regarding the side-effects of Tafero 25 mg (Tenofovir Alafenamide) for more information.

Warnings associated with Tafero 25 mg (Tenofovir Alafenamide):

• Discontinuation of treatment leading to severe acute liver complications: Patients are strictly forbidden to stop their current dosing schedule as such decisions could cause severe problems in the liver.

• Risk of developing HIV-1 resistance in patients with HIV-1 coinfection: If patients already have HIV infection and have not received any cure, this drug might increase resistance to HIV medications.

• New onset or worsening condition of the kidney: If patients have any sort of problems in the kidney (end-stage renal disease), avoid using tenofovir-based medications for decreasing any chances of acute kidney failure.

• Missed dosage leading to resistance: Patients should take the dosage as prescribed by their doctor. If patients miss even a single dose, the viral cells may develop resistance against Tafero 25 mg (Tenofovir alafenamide).

• Drug interactions: Patients are obliged to inform about all medicines they are taking other than Tafero 25 mg (Tenofovir alafenamide).

• Pregnancy-related issues: Discuss the pregnancy and breastfeeding issues with your doctor.